Latest hypoglycemia Stories

PRINCETON, N.J. and INDIANAPOLIS, Ind., Nov. 15, 2011 /PRNewswire/ -- Novo Nordisk, a world leader in diabetes care, and Chip Ganassi Racing Teams, Inc. announced today that the two organizations have entered into a multi-year extension of their partnership. Novo Nordisk will remain the primary sponsor of the No. 83 Novo Nordisk Chip Ganassi Racing entry, driven by Charlie Kimball in the IZOD IndyCar Series. To view the multimedia assets associated with this release, please click:...

DALLAS, Nov. 14, 2011 /PRNewswire/ -- Meals to Live, the first and only grocery store line of frozen meals created specifically for people living with diabetes, adds a new product to its line - Glucose Quick Sticks, an easy-to-carry, quick-dissolving flavored powder packet that provides a healthy boost of glucose for those with challenges. Hypoglycemia (low blood sugar) is a complication that can affect anyone living with diabetes. Meals to Live's Glucose Quick Sticks come in two tasty...

PRINCETON, N.J., Nov. 2, 2011 /PRNewswire/ -- Novo Nordisk, a world leader in diabetes care, announced today that it has donated $50,000 to the Diabetes Hands Foundation (DHF), a non-profit organization that raises diabetes awareness and connects people touched by the condition. The donation recognizes the success of the Drive the Switch program, which has motivated more than 10,000 people to pledge to talk to loved ones and their doctor about options for insulin delivery, like the...

DALLAS, Nov. 02, 2011 /PRNewswire/ -- November marks National Diabetes Awareness Month, and Meals to Live, the first grocery store line of frozen meals designed for the needs of consumers living with diabetes, will give away 500 free meals to help educate people about the disease that affects nearly 26 million Americans. Meals to Live offers innovatively packaged, great tasting and convenient options to help people living with diabetes manage their nutritional requirements. With...

CARLSBAD, Calif., Nov. 2, 2011 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has initiated Phase 1 clinical studies for ISIS-GCGRRx and ISIS-GCCRRx, antisense drugs Isis is developing for the treatment of type 2 diabetes. Isis will develop both ISIS-GCGRRx and ISIS-GCCRRx to treat a broad population of diabetic patients. The unique mechanism of action of these new drugs could allow each drug to be used in combination with other therapies for type 2...

SAN DIEGO, Oct. 21, 2011 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the diabetes, cancer, dermatology and drug delivery markets, today announced positive results from two Phase 2 clinical trials of its ultrafast PH20 insulin analog formulations in patients with Type 1 and Type 2 diabetes. Both trials met the primary endpoint of non-inferiority of HbA1C compared to the...

Patients with diabetes face daily challenges in managing their blood glucose levels, and it has been postulated that patients could benefit from a system providing continuous real-time glucose readings. Today, The Endocrine Society released a clinical practice guideline (CPG) providing recommendations on settings where patients are most likely to benefit from continuous glucose monitoring (CGM). The most common way to self-check blood glucose levels is to prick the skin to get a drop of...

A team of researchers at the University of Sydney in Australia has discovered a new food insulin index (FII) algorithm for use in estimating the amount of insulin that Type 1 diabetics should receive when eating meals as reported by DiabeticLive.com. Orlando, FL (PRWEB) October 07, 2011 Algorithm for Estimating Mealtime Insulin Dose More Effective than Carb Counting: A team of researchers at the University of Sydney in Australia has discovered a new food insulin index (FII) algorithm for...

Research provides the prospect of effective drug treatments for the genetic disorder Cambridge scientists have identified the cause of a rare, life-threatening form of hypoglycemia. Their findings, which have the potential to lead to pharmaceutical treatments for the disorder, were published today, 07 October, in the journal Science. Hypoglycemia, usually characterized by too much insulin which results in too little sugar in the bloodstream, is fairly common, often affecting diabetic...

(Ivanhoe Newswire) -- People with type 2 diabetes who intensively lower their blood sugar are not preventing cognitive decline, according to new research. Individuals with type 2 diabetes who are older than age 70 are twice as likely to develop cognitive impairment that is linked to their disease than those without diabetes. A team of researchers studied nearly 3,000 patients aged 55 years who had type 2 diabetes and were at risk for cardiovascular disease. These individuals also had...